Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

On the Probabilistic Deployment of Smart Grid Networks in TV White Space.

Cacciapuoti AS, Caleffi M, Paura L.

Sensors (Basel). 2016 May 10;16(5). pii: E671. doi: 10.3390/s16050671.

2.

On the Achievable Throughput Over TVWS Sensor Networks.

Caleffi M, Cacciapuoti AS.

Sensors (Basel). 2016 Mar 30;16(4):457. doi: 10.3390/s16040457.

3.

The optimization of pyridazinone series of glucan synthase inhibitors.

Kuang R, Wu H, Ting PC, Aslanian RG, Cao J, Kim DW, Lee JF, Schwerdt J, Zhou G, Herr RJ, Zych AJ, Yang J, Lam SQ, Jenkins DM, Sakwa SA, Wainhaus S, Black TA, Cacciapuoti A, McNicholas PM, Xu Y, Walker SS.

Bioorg Med Chem Lett. 2012 Aug 15;22(16):5268-71. doi: 10.1016/j.bmcl.2012.06.091. Epub 2012 Jul 4.

PMID:
22818082
4.

Lead optimization of a sulfonylurea-based piperazine pyridazinone series of glucan synthase inhibitors.

Zych AJ, Lam SQ, Jenkins DM, Herr RJ, Ting PC, Lee JF, Kuang R, Wu H, Kim DW, Aslanian RG, Wainhaus S, Black TA, Cacciapuoti A, McNicholas PM, Xu Y, Walker SS.

Bioorg Med Chem Lett. 2012 Jul 15;22(14):4896-9. doi: 10.1016/j.bmcl.2012.04.127. Epub 2012 May 17.

PMID:
22687744
5.

Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors.

Walker SS, Xu Y, Triantafyllou I, Waldman MF, Mendrick C, Brown N, Mann P, Chau A, Patel R, Bauman N, Norris C, Antonacci B, Gurnani M, Cacciapuoti A, McNicholas PM, Wainhaus S, Herr RJ, Kuang R, Aslanian RG, Ting PC, Black TA.

Antimicrob Agents Chemother. 2011 Nov;55(11):5099-106. doi: 10.1128/AAC.00432-11. Epub 2011 Aug 15.

6.

The synthesis and structure-activity relationship of pyridazinones as glucan synthase inhibitors.

Ting PC, Kuang R, Wu H, Aslanian RG, Cao J, Kim DW, Lee JF, Schwerdt J, Zhou G, Wainhaus S, Black TA, Cacciapuoti A, McNicholas PM, Xu Y, Walker SS.

Bioorg Med Chem Lett. 2011 Mar 15;21(6):1819-22. doi: 10.1016/j.bmcl.2011.01.058. Epub 2011 Jan 21.

PMID:
21316223
7.

Posaconazole (Noxafil, SCH 56592), a new azole antifungal drug, was a discovery based on the isolation and mass spectral characterization of a circulating metabolite of an earlier lead (SCH 51048).

Nomeir AA, Pramanik BN, Heimark L, Bennett F, Veals J, Bartner P, Hilbert M, Saksena A, McNamara P, Girijavallabhan V, Ganguly AK, Lovey R, Pike R, Wang H, Liu YT, Kumari P, Korfmacher W, Lin CC, Cacciapuoti A, Loebenberg D, Hare R, Miller G, Pickett C.

J Mass Spectrom. 2008 Apr;43(4):509-17.

PMID:
18059003
8.

Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats.

Ullmann AJ, Krammes E, Sommer S, Buschmann I, Jahn-Muehl B, Cacciapuoti A, Schmitt HJ.

J Antimicrob Chemother. 2007 Nov;60(5):1080-4. Epub 2007 Sep 12.

PMID:
17855727
9.

Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.

Cacciapuoti A, Halpern J, Mendrick C, Norris C, Patel R, Loebenberg D.

Antimicrob Agents Chemother. 2006 Jul;50(7):2587-90.

10.

Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5].

Bennett F, Saksena AK, Lovey RG, Liu YT, Patel NM, Pinto P, Pike R, Jao E, Girijavallabhan VM, Ganguly AK, Loebenberg D, Wang H, Cacciapuoti A, Moss E, Menzel F, Hare RS, Nomeir A.

Bioorg Med Chem Lett. 2006 Jan 1;16(1):186-90. Epub 2005 Nov 2.

PMID:
16260134
11.

Inactivation of sterol Delta5,6-desaturase attenuates virulence in Candida albicans.

Chau AS, Gurnani M, Hawkinson R, Laverdiere M, Cacciapuoti A, McNicholas PM.

Antimicrob Agents Chemother. 2005 Sep;49(9):3646-51.

12.

Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo.

Cacciapuoti A, Gurnani M, Halpern J, Norris C, Patel R, Loebenberg D.

Antimicrob Agents Chemother. 2005 Feb;49(2):638-42.

13.

Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis.

Patera AC, Menzel F, Jackson C, Brieland JK, Halpern J, Hare R, Cacciapuoti A, Loebenberg D.

Antimicrob Agents Chemother. 2004 Aug;48(8):3154-8.

14.

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories.

Najvar LK, Cacciapuoti A, Hernandez S, Halpern J, Bocanegra R, Gurnani M, Menzel F, Loebenberg D, Graybill JR.

Antimicrob Agents Chemother. 2004 Mar;48(3):758-64.

15.

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.

Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cacciapuoti A, Loebenberg D.

Antimicrob Agents Chemother. 2004 Jan;48(1):137-42.

16.

Levobupivacaina, bupivacaina racemica e ropivacaina nel blocco del plesso brachiale.

Cacciapuoti A, Castello G, Francesco A.

Minerva Anestesiol. 2002 Jul-Aug;68(7-8):599-605. English, Italian.

PMID:
12244291
17.

Synthesis and antifungal activity of the 2,2,5-tetrahydrofuran regioisomers of SCH 51048.

Lovey RG, Saksena AK, Girijavallabhan VM, Blundell P, Guzik H, Loebenberg D, Parmegiani RM, Cacciapuoti A.

Bioorg Med Chem Lett. 2002 Jul 8;12(13):1739-42.

PMID:
12067550
18.

Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.

Pavia CS, Wormser GP, Nowakowski J, Cacciapuoti A.

Antimicrob Agents Chemother. 2001 Mar;45(3):936-7.

19.

Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus.

Brieland JK, Jackson C, Menzel F, Loebenberg D, Cacciapuoti A, Halpern J, Hurst S, Muchamuel T, Debets R, Kastelein R, Churakova T, Abrams J, Hare R, O'Garra A.

Infect Immun. 2001 Mar;69(3):1554-60.

20.

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.

Cacciapuoti A, Loebenberg D, Corcoran E, Menzel F Jr, Moss EL Jr, Norris C, Michalski M, Raynor K, Halpern J, Mendrick C, Arnold B, Antonacci B, Parmegiani R, Yarosh-Tomaine T, Miller GH, Hare RS.

Antimicrob Agents Chemother. 2000 Aug;44(8):2017-22.

21.

[A case of tetanus: the problem of differential diagnosis].

Castello G, Cacciapuoti A, Stellino MB.

Minerva Anestesiol. 2000 Jan-Feb;66(1-2):69-72. Italian.

PMID:
10736985
22.

Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys.

Nomeir AA, Kumari P, Hilbert MJ, Gupta S, Loebenberg D, Cacciapuoti A, Hare R, Miller GH, Lin CC, Cayen MN.

Antimicrob Agents Chemother. 2000 Mar;44(3):727-31.

23.

Nonfilamentous C. albicans mutants are avirulent.

Lo HJ, Köhler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR.

Cell. 1997 Sep 5;90(5):939-49.

24.

Relationship among physicochemical properties, skin permeability, and topical activity of the racemic compound and pure enantiomers of a new antifungal.

Wearley L, Antonacci B, Cacciapuoti A, Assenza S, Chaudry I, Eckhart C, Levine N, Loebenberg D, Norris C, Parmegiani R, et al.

Pharm Res. 1993 Jan;10(1):136-40.

PMID:
8430050
25.

Sch 39304, a new antifungal agent: oral and topical treatment of vaginal and superficial infections.

Parmegiani RM, Loebenberg D, Cacciapuoti A, Antonacci B, Norris C, Menzel F, Moss L, Yarosh-Tomaine T, Hare RS, Miller GH.

J Med Vet Mycol. 1993;31(3):239-48.

PMID:
8360815
26.

In vitro and in vivo activities of SCH 42427, the active enantiomer of the antifungal agent SCH 39304.

Loebenberg D, Cacciapuoti A, Parmegiani R, Moss EL Jr, Menzel F Jr, Antonacci B, Norris C, Yarosh-Tomaine T, Hare RS, Miller GH.

Antimicrob Agents Chemother. 1992 Feb;36(2):498-501.

27.

Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice.

Cacciapuoti A, Loebenberg D, Parmegiani R, Antonacci B, Norris C, Moss EL Jr, Menzel F Jr, Yarosh-Tomaine T, Hare RS, Miller GH.

Antimicrob Agents Chemother. 1992 Jan;36(1):64-7.

28.

Microbiological and pharmacokinetic studies of acyl demycinosyltylosin and related tylosin derivatives.

Cacciapuoti AF, Loebenberg D, Moss EL Jr, Menzel FW, Rudeen JA, Naples LR, Cramer CL, Hare RS, Mallams AK, Miller GH.

J Antibiot (Tokyo). 1990 Sep;43(9):1131-6.

29.

In vitro and in vivo characterization of novel 8-methoxy derivatives of chlortetracycline.

Cacciapuoti A, Moss EL Jr, Menzel F Jr, Cramer CA, Weiss W, Loebenberg D, Hare RS, Miller GH.

J Antibiot (Tokyo). 1987 Oct;40(10):1426-30.

30.

In-vitro activity of Sch 34343 against Gram-negative bacteria producing characterized beta-lactamases.

Dornbusch K, Frolander F, Cacciapuoti AF, Naples L, Hare RS, Miller GH.

J Antimicrob Chemother. 1985 Jun;15 Suppl C:85-97.

PMID:
3897175
31.

Regulation of bile acid 7-dehydroxylase activity by NAD+ and NADH in cell extracts of Eubacterium species V.P.I. 12708.

White BA, Paone DA, Cacciapuoti AF, Fricke RJ, Mosbach EH, Hylemon PB.

J Lipid Res. 1983 Jan;24(1):20-7.

32.

[Determination of tissue creatine phosphokinase as a direct enzymatic method for evaluation of the area of necrosis in rats with isoproterenol-induced infarctions].

Latte S, Genovese A, De Alfieri W, Polverino W, Cacciapuoti AA, Romano M, Chiariello M.

Minerva Cardioangiol. 1981 Nov;29(11):599-602. Italian. No abstract available.

PMID:
7329563
33.
34.

7 alpha-Dehydroxylation of cholic acid by cell extracts of Eubacterium species V.P.I. 12708.

Hylemon PB, Cacciapuoti AF, White BA, Whitehead TR, Fricke RJ.

Am J Clin Nutr. 1980 Nov;33(11 Suppl):2507-10. doi: 10.1093/ajcn/33.11.2507.

PMID:
7435421
35.

Inhibition of hypoxia-induced cardiac hypertrophy by verapamil in rats.

Genovese A, Chiariello M, Cacciapuoti AA, De Alfieri W, Latte S, Condorelli M.

Basic Res Cardiol. 1980 Nov-Dec;75(6):757-63.

PMID:
6452122
37.

Myocardial hypertrophy in the rat. Correlation between two experimental models.

Genovese A, Chiariello M, Ferro G, Cacciapuoti AA, Condorelli M.

Jpn Heart J. 1980 Jul;21(4):511-7.

PMID:
6448306
38.

[Complete left branch block during treatment with adriamycin. Description of a clinical case].

Polverino W, Basso A, Genovese A, De Alfieri W, Latte S, Cacciapuoti AA, Carone T.

Minerva Cardioangiol. 1980 Jun;28(6):457-62. Italian. No abstract available.

PMID:
7242932
39.

Effects of antiplatelet and calcium antagonist drugs on infarct size in rats.

Genovese A, Chiariello M, Latte S, de Alfieri W, Cacciapuoti AA, Condorelli M.

Acta Cardiol. 1980;35(6):419-27.

PMID:
6785949
40.

[Pharmacological protection of the cardiac mucle in experimental infarct. II. Effects of verapamil].

Polverino W, Genovese A, Cacciapuoti AA, Latte S, Petillo F, Basso A, Condorelli M.

Minerva Cardioangiol. 1979 Dec;27(12):789-92. Italian. No abstract available.

PMID:
550092
41.

[The role of calcium in the pathogenesis of experimental infarct induced with isoproterenol in the rat. Preliminary findings. I].

Genovese A, Cacciapuoti AA, Polverino W, Chiariello M, De Alfieri W, Condorelli M.

Minerva Cardioangiol. 1979 Dec;27(12):783-8. Italian. No abstract available.

PMID:
550091
42.

[Effects of inhibitors of protein synthesis on myocardial hypertrophy caused by acute hypobaric hypoxia in rats].

Genovese A, Polverino W, Cacciapuoti AA, Condorelli M.

Minerva Cardioangiol. 1979 Sep;27(9):547-50. Italian. No abstract available.

PMID:
161995
43.

Phospholipid metabolism in Neisseria gonorrhoeae: phospholipid hydrolysis in nongrowing cells.

Cacciapuoti AF, Wegener WS, Morse SA.

Lipids. 1979 Aug;14(8):718-26.

PMID:
43450
44.

[The role of the platelets in myocardial infarction induced by isoproterenol in the rat (author's transl)].

Cacciapuoti AA, Giuffrida G, Mazza F, Polverino W, Genovese A.

G Ital Cardiol. 1979;9(7):767-8. Italian.

PMID:
540709
45.

[Myocardial hypertrophy in the course of experimental infarct in the rat].

Genovese A, Cacciapuoti AA, Polverino W, Condorelli M.

G Ital Cardiol. 1979;9(4):406-10. Italian. No abstract available.

PMID:
156663
46.

Physiology of Neisseria gonorrhoeae.

Morse SA, Cacciapuoti AF, Lysko PG.

Adv Microb Physiol. 1979;20:251-320. Review. No abstract available.

PMID:
43667
47.

Cell envelope of Neisseria gonorrhoeae: phospholipase activity and its relationship to autolysis.

Cacciapuoti AF, Wegener WS, Morse SA.

Infect Immun. 1978 May;20(2):418-20.

48.

Erythroid colony formation and erythropoietin activity in mice treated with estradiol benzoate.

Peschle C, Magli MC, Cillo C, Lettieri F, Cacciapuoti A, Pizzella F, Marone G.

Life Sci. 1977 Nov 1;21(9):1303-10. No abstract available.

PMID:
927031
49.
50.

[Myocardial hypertrophy caused by hypobaric hypoxia. Studies in male and female rats of various ages].

Buccelli C, Meccariello P, Cacciapuoti A, Errico R, Critelli G, Peschle C.

Boll Soc Ital Cardiol. 1975;20(12):1860-6. Italian. No abstract available.

PMID:
136262

Supplemental Content

Loading ...
Support Center